NEK6 Kinase Inhibitors for Selective Solid Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antitumor drugs lack selectivity for malignant cells, leading to limited clinical results due to cytotoxicity in normal cells, and there is a need for targeted therapies against NEK6, a protein involved in tumorigenesis and mitotic processes.
Innovation Solution
Development of compounds with specific inhibitory activity against NEK6, such as those with general formulas (A) and (B), which inhibit NEK6 kinase activity and demonstrate synergistic effects when combined with chemotherapeutic drugs, thereby selectively targeting tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antitumor drugs are used to stop cell cycle during mitosis, then cell division is inhibited, but cytotoxicity on normal cells occurs leading to limited therapeutic index
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target NEK6 kinase activity in tumor cells through selective binding to the ATP-binding site. The molecular structures (formulas A and B) are engineered with specific substituents (R1, R2, R3 groups) that provide selective affinity for NEK6 over other kinases, enabling localized inhibition of mitotic processes in malignant cells while sparing normal cells from cytotoxic effects.
Solution Approach 2:
The patent employs parameter changes by modifying chemical parameters of the inhibitor molecules to optimize selectivity and potency. The structures include variable substituents (R1 from formula A, R from formula B) that can be tuned to alter binding affinity, specificity, and pharmacokinetic properties, thereby improving the therapeutic index through precise parameter optimization rather than broad-spectrum inhibition.
2Reliability
If NEK6 inhibition is achieved through RNA silencing or inactive mutants, then mitotic stop and apoptosis occur in tumor cells, but the approach lacks direct pharmacological inhibition
Solution Approach 1:
The patent replaces the mechanical/biological approach of RNA silencing and protein mutagenesis with a chemical/pharmacological approach. Instead of using molecular biology techniques to deplete NEK6 or create inactive mutants, the invention uses small molecule inhibitors that directly bind to and inhibit NEK6 kinase activity, achieving the same apoptotic outcome through a more clinically translatable mechanism.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that mediate the inhibition of NEK6. These compounds (formulas A and B) act as chemical messengers that transmit the inhibitory signal to the NEK6 kinase, bridging the gap between external administration and intracellular target engagement, thereby enabling pharmacological control of tumor cell apoptosis.
3Reliability
If selective NEK6 inhibitors are developed, then therapeutic effectiveness is improved, but compound structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a core heterocyclic structure (pyridine in formula A, triazatetracycle in formula B) and variable substituent groups (R1, R2, R3, R). This modular segmentation allows for systematic optimization of each segment's contribution to selectivity and potency, managing structural complexity through organized functional decomposition rather than monolithic design.
Solution Approach 2:
The patent employs universality by designing a platform of compounds with a common core structure that can inhibit NEK6 through a shared mechanism of action. The core heterocyclic framework provides universal binding to the NEK6 ATP-site, while variable substituents allow adaptation to different tumor types and resistance scenarios, making the inhibitor class universally applicable across multiple indications while managing complexity through structural commonality.
Data Source
AI summary
The mitotic kinases regulating the dynamics of centrosomes and the functions of the mitotic spindle are potential targets for the antitumour therapy. In the present invention some molecules with inhibitory activity on NEK6 have been identified. The present invention relates to such molecules and to the compositions including them for use as inhibitors of NEK6 in a method of treatment of tumours both in monotherapy and in combinations with other drugs.